Partnership Expansion Medipost’s ongoing collaboration with external R&D and manufacturing partners (CCRM, OmniaBio) signals strong interest in expanding global production and GMP testing capabilities. Approach potential biotech CROs/CDMOs and national health systems about joint development and regional manufacturing agreements to accelerate CARTISTEM access.

Korea to Global CARTISTEM has established regulatory and commercial traction in Korea with widespread patient adoption and a late-stage US development program. Target market entry strategies for Japan, North America, and other high-potential regions where regulatory pathways for allogeneic stem cell therapies are maturing.

Financing Momentum Recent $140M financing indicates investor confidence and public market readiness for scale. Leverage this momentum to pursue strategic partnerships, co-development deals, and milestone-driven collaborations with larger biopharma players seeking cell therapy platforms.

Commercial Licensing Exclusive and non-exclusive licensing activity—such as the Japan commercialization agreement—demonstrates appetite for regional rights. Identify additional territory licensing opportunities and post-marketing support services to broaden CARTISTEM’s geographic footprint.

Manufacturing Readiness OmniaBio’s CDMO capabilities position Medipost to offer end-to-end manufacturing services for allogeneic cell therapies. Propose bundled solutions combining development, scale-up, and manufacturing for potential partners pursuing compatible inflammatory or degenerative disease programs.